Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rapport Therapeutics, Inc. ( (RAPP) ) has shared an announcement.
On June 2, 2025, Rapport Therapeutics announced that its Phase 2a trial for RAP-219 in refractory focal epilepsy is fully enrolled, with results expected in September 2025. The company also shared data from completed Phase 1 trials, highlighting RAP-219’s tolerability and lack of serious adverse events. This progress underscores Rapport’s strategic focus on advancing its clinical pipeline and potentially enhancing its market position in treating neurological disorders.
The most recent analyst rating on (RAPP) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Rapport Therapeutics, Inc. stock, see the RAPP Stock Forecast page.
Spark’s Take on RAPP Stock
According to Spark, TipRanks’ AI Analyst, RAPP is a Neutral.
Rapport Therapeutics, Inc. faces significant challenges with no revenue and substantial operational losses despite strong equity financing and low leverage. Technical indicators point to a downward trend, and valuation is difficult to ascertain. Positive clinical trial results offer some optimism, but leadership changes contribute to uncertainty.
To see Spark’s full report on RAPP stock, click here.
More about Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of precision medicines for neurological and psychiatric disorders. The company leverages its RAP technology platform to create small molecule drugs with high selectivity and specificity, aiming to transform treatment in these fields.
Average Trading Volume: 232,248
Technical Sentiment Signal: Strong Sell
Current Market Cap: $301.8M
See more insights into RAPP stock on TipRanks’ Stock Analysis page.